{"filings":[{"id":442918,"accession_number":"0001193125-26-224069","cik":1774857,"company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","form_type":"8-K","filed_at":"2026-05-14T20:15:34+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA places full clinical hold on Aardvark's ARD-101 IND; HERO and OLE trials paused","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA full clinical hold on IND for ARD-101, affecting Phase 3 HERO trial (AVK-101-301) and OLE trial (AVK-101-302).","Company to unblind accumulated data from 68 HERO patients and 19 OLE patients to inform next steps.","Cash of $91.2M as of March 31, 2026, expected to fund operations into mid-2027.","Active discussions with FDA ongoing to resolve clinical hold and determine path forward."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":87810950.48245613,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95350,"accession_number":"0001193125-26-210664","cik":1774857,"company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aardvark Q1 net loss $21.6M; ARD-101/ARD-201 programs on voluntary pause","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $21.6M for Q1 2026 vs. $9.3M for Q1 2025, driven by higher R&D expenses.","Cash, cash equivalents and ST investments at $91.2M (down from $110.0M Dec 31, 2025); runway into mid-2027.","R&D expenses $16.6M (up $8.8M YoY) due to ARD-101 development and personnel costs.","Voluntary pause on Phase 3 HERO trial and ARD-201 after reversible cardiac signals in a healthy volunteer study.","Company working with FDA and expects to provide program guidance in Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":87810950.48245613,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108343,"accession_number":"0001193125-26-120164","cik":1774857,"company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aardvark enters $150M equity distribution agreement with Piper Sandler","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["May sell up to $150M of common stock at market through Piper Sandler as agent.","Commission of 3.0% of gross sales price per share sold under agreement.","Company has no obligation to sell any shares; sales at Company's discretion.","Agreement filed as Exhibit 10.1; shelf registration on Form S-3 filed same day."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":87810950.48245613,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108342,"accession_number":"0001193125-26-119727","cik":1774857,"company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aardvark Therapeutics reports FY2025 net loss $57.6M; pauses all clinical trials after cardiac signal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $57.6M for FY2025 vs $20.6M in FY2024; cash $110.0M supports operations into Q2 2027.","Voluntary pause of Phase 3 HERO and OLE trials for ARD-101 in PWS after reversible QRS prolongation in healthy volunteers.","ARD-201 obesity trials (POWER, STRENGTH) also voluntarily paused; further guidance expected Q2 2026.","Clinical and preclinical data published in Molecular Metabolism showing ARD-101 reduced hunger and increased gut hormones.","R&D spend $48.9M in FY2025 up from $17.4M; G&A $13.8M up from $5.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":87810950.48245613,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108341,"accession_number":"0001193125-26-082787","cik":1774857,"company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aardvark Therapeutics pauses Phase 3 HERO trial for ARD-101 in PWS due to cardiac signals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Voluntary pause of Phase 3 HERO trial (NCT06828861) and open-label extension (NCT07197034) for ARD-101 in Prader-Willi Syndrome.","Decision based on reversible cardiac observations at above-target therapeutic doses in a healthy volunteer study.","No longer expects topline data in Q3 2026; plans to provide guidance in Q2 2026.","Company conducting comprehensive data review and collaborating with FDA and clinical experts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":87810950.48245613,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108340,"accession_number":"0001193125-26-047757","cik":1774857,"company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Aardvark COO exits to lead new dermatology subsidiary; CFO Sun adds COO role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bryan Jones stepped down as COO of Aardvark on Feb 9, 2026, to become CEO of wholly-owned subsidiary Ardia Therapeutics.","Ardia will develop DIA-615, a topical treatment for inflammatory skin diseases including psoriasis.","CFO Nelson Sun appointed COO in addition to his CFO role, effective Feb 9, 2026; no compensation change.","Derrick C. Li appointed Chief Business Officer, effective Feb 9, 2026.","Jones received accelerated vesting of 17,797 shares and continued option exercise while at Ardia; waived severance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":87810950.48245613,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108339,"accession_number":"0001193125-26-043764","cik":1774857,"company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aardvark Therapeutics expands Phase 3 HERO trial age eligibility to 7+ years for ARD-101 in PWS","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["IRB approved amended protocol lowering minimum age from 10 to 7 years for Phase 3 HERO trial evaluating ARD-101.","Amended protocol submitted to FDA; enrollment on track for topline data in Q3 2026.","Trial targets 90 patients across US, Australia, Canada, UK, and South Korea.","Primary endpoint: change in HQ-CT score at 12 weeks; open-label extension offered to completers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":87810950.48245613,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108338,"accession_number":"0001193125-26-009862","cik":1774857,"company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aardvark Therapeutics files updated corporate presentation; no material disclosures.","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate presentation dated January 2026 filed with SEC.","No specific operational, financial, or clinical updates disclosed in the filing.","Presentation intended for use in investor meetings and posted to company website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":87810950.48245613,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124793,"accession_number":"0001193125-25-314364","cik":1774857,"company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aardvark doses first patient in Australia Phase 3 HERO trial; Q3 2026 data readout on track","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Australia in Phase 3 HERO trial for ARD-101 for hyperphagia in Prader-Willi syndrome.","Regulatory clearance received for clinical trial sites in Canada and UK; EU sites not needed for full enrollment.","All patients completing the 12-week HERO trial have enrolled in the Open Label Extension, indicating strong patient interest.","Topline data readout remains on track for Q3 2026 driven by strong US enrollment and international progress."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":87810950.48245613,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124792,"accession_number":"0001193125-25-280235","cik":1774857,"company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aardvark Therapeutics Q3 net loss $16.3M; cash $126.4M; FDA expands PWS trial age to 10 years","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and short-term investments of $126.4M as of Sep 30, 2025; expected to fund operations into 2027.","Net loss of $16.3M for Q3 2025 vs $4.2M for Q3 2024, driven by increased R&D and G&A expenses.","R&D expenses $13.7M (vs $4.1M) and G&A expenses $4.0M (vs $1.0M) due to ARD-101 development and public company costs.","FDA agreed to reduce minimum age for HERO Phase 3 trial (ARD-101 for PWS) from 13 to 10 years, broadening eligibility.","Preclinical ARD-201 data showed preserved lean mass, glucose control vs tirzepatide, and weight management post-GLP-1."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":87810950.48245613,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124791,"accession_number":"0001193125-25-267402","cik":1774857,"company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aardvark Therapeutics reviews ARD-101 and ARD-201 programs at investor webinar; no new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed presentation lacks specific clinical results or financial figures.","Webinar covered ARD-101 and ARD-201 programs and ObesityWeek 2025 presentations.","Materiality is limited as filing is a procedural update without substantive new information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":87810950.48245613,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124790,"accession_number":"0001193125-25-264748","cik":1774857,"company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Aardvark reports ARD-201 preserved lean mass, reduced weight; WE-868 shows >10% weight loss in mCRC patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ARD-201 (ARD-101+sitagliptin) in DIO mice reduced body weight ~19% in 30 days, comparable to high-dose tirzepatide, and preserved lean mass.","In Phase 2a, ARD-101 reduced hunger (CoEQ) and showed weight control signals, well-tolerated with no serious AEs in 14 adults with obesity.","WE-868 (OxPhos modulator) induced >10% average weight loss in mCRC patients over median 10 weeks; in DIO mice, weight loss exceeded semaglutide at 50 mg/kg.","Aardvark plans to start Phase 2 POWER trial (weight regain prevention) for ARD-201 by end 2025; investor webinar scheduled for Nov 5."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":87810950.48245613,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124789,"accession_number":"0001193125-25-234722","cik":1774857,"company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aardvark gets FDA alignment to lower Phase 3 PWS trial min age to 10","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA aligned on protocol amendment for Phase 3 HERO trial of ARD-101, lowering minimum age from 13 to 10 years old.","Expansion broadens patient population in Prader-Willi Syndrome; topline data readout expected in Q3 2026.","CEO cites community support and historical data suggesting younger patients benefit from early intervention."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":87810950.48245613,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141486,"accession_number":"0000950170-25-112645","cik":1774857,"company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aardvark Therapeutics updates corporate presentation; no material specifics disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company updated corporate presentation dated September 2025 for investor meetings.","Filing includes only cover and disclaimer; no pipeline, financial, or guidance changes detailed.","No specific numbers or events from the presentation were included in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":87810950.48245613,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141485,"accession_number":"0000950170-25-108082","cik":1774857,"company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aardvark Therapeutics Q2 net loss $14.4M; advances ARD-201 obesity trials and expands PWS trial to younger patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.4M in Q2 2025 vs $5.4M in Q2 2024; R&D expenses rose to $13.1M.","Cash, cash equivalents, and short-term investments of $141.8M as of June 30, 2025; funds operations into 2027.","Preclinical data shows ARD-201 prevents weight regain after GLP-1RA discontinuation; Phase 2 POWER trial in H2 2025, STRENGTH in H1 2026.","Phase 3 HERO trial for ARD-101 in PWS to expand to patients under 13; topline data expected Q3 2026.","Appointed new CSO, CCO, SVP Regulatory, and General Counsel in May 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":87810950.48245613,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141484,"accession_number":"0000950170-25-107320","cik":1774857,"company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aardvark reports ARD-201 preclinical data: 19% weight loss in mice; plans two Phase 2 trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ARD-201 monotherapy achieved ~19% body weight reduction in DIO mice after 30 days.","ARD-201 attenuated weight regain after tirzepatide withdrawal; combo with low-dose tirzepatide outperformed high-dose tirzepatide alone.","Phase 2 POWER trial (2H 2025) targets weight regain prevention in patients discontinuing GLP-1RA therapy.","Phase 2 STRENGTH trial (1H 2026) to test monotherapy and combination with GLP-1RA, replacing prior EMPOWER trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":87810950.48245613,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159329,"accession_number":"0000950170-25-071477","cik":1774857,"company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aardvark Therapeutics Q1 net loss $9.3M; cash $151.3M; Phase 3 PWS data expected early 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss was $9.3M in Q1 2025 vs $2.2M in Q1 2024, driven by higher R&D and G&A costs.","R&D expenses rose to $7.8M (from $1.2M) due to ARD-101 development and personnel costs.","Cash, equivalents and short-term investments totaled $151.3M; IPO net proceeds were $87.5M.","Phase 3 HERO trial of ARD-101 for Prader-Willi syndrome; top-line data readout expected early 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":87810950.48245613,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177741,"accession_number":"0000950170-25-047769","cik":1774857,"company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aardvark Therapeutics reports FY 2024 net loss $20.6M; advances ARD-101 Phase 3 PWS trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $20.6M in 2024 vs $7.2M in 2023; R&D expenses $17.4M (up $12.9M YoY).","Cash, equivalents, and ST investments $73.7M at Dec 31, 2024; plus $97.9M IPO gross proceeds in Feb 2025.","ARD-101 Phase 2 PWS data: up to 16-point HQ-CT reduction in hyperphagia; body fat decreased ~1.5%, lean muscle increased >2%.","Phase 3 HERO trial topline data for PWS expected early 2026; Phase 2 HONOR (hypothalamic obesity) and EMPOWER (obesity/ARD-201 combo) expected H2 2025.","Appointed Manasi Sinha Jaiman as CMO; added Roy D. Baynes and Susan E. Graf to Board."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":87810950.48245613,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177740,"accession_number":"0001193125-25-027245","cik":1774857,"company_name":"Aardvark Therapeutics, Inc.","ticker":"AARD","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Aardvark Therapeutics completes IPO; issues 5.888M shares at $16.00, raises $94.2M gross","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of 5,888,000 shares at $16.00 per share completed on Feb 14, 2025.","Gross proceeds $94.2M before underwriting discounts and commissions.","Amended certificate authorizes 490M common shares and 10M preferred shares.","Amended bylaws establish classified board, stockholder proposal procedures, and exclusive forum provision.","Common stock trades on Nasdaq under ticker AARD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":87810950.48245613,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}